Qsymia is a weight loss drug engineered by the California-based pharmaceutical company Vivus Inc. It was initially approved by the FDA in 2012 for weight reduction among adults with BMIs (body mass indexes) exceeding 30 kg/m² as an adjunct to interventions such as caloric restriction, dietary modification, and regular exercise. Qsymia is also approved for …
Acupuncture is a form of complementary alternative medicine (CAM) in which a practitioner (acupuncturist) stimulates the skin of his/her client transcutaneously [with needles] or transdermally [with electrical pulses or lasers]. According to proponents of traditional Chinese medicine, the precise stimulation of sites across the skin (referred to as “acupuncture points”) modulates the flow of energy …
Naltrexone is a pure opioid receptor antagonist utilized principally for the treatment of alcohol and opioid dependence. As an opioid receptor antagonist, naltrexone competitively binds to mu-opioid receptor (MOR) and kappa-opioid receptor (KOR) sites with higher affinity than opioid agonists, thereby attenuating receptor activation. Should an individual administer an opioid agonist (e.g. morphine) while taking …
Zomig (Zolmitriptan) is a medication marketed by AstraZeneca and is FDA-approved as an abortive therapy for migraines and cluster headaches. Chemically, it’s classified as a triptan implying that it’s a tryptamine-derivative, and is manufactured in multiple formats including: tablet and nasal spray. Similar to other triptans, Zomig is considered efficacious when administered during a migraine …
Maxalt (Rizatriptan) is a pharmaceutical medication engineered by Merck & Co. for the treatment of migraine headaches (with or without aura). It received FDA approval in 1998 as an abortive antimigraine intervention and is chemically classified as a second-generation triptan (tryptamine-based). Analogous to other triptans, Rizatriptan remains ineffective as a migraine prophylactic, however, it is …
Relpax (Eletriptan) is a medication manufactured by Pfizer Inc. for the acute treatment of migraine headaches (with or without aura) in adults. It was initially approved by the FDA in 2002 and is regarded as a highly effective abortive agent, engineered to attenuate already-occurring migraine attacks. Chemically, Relpax is classified as a second generation triptan …
Sumatriptan (brand names “Imitrex”) is a synthetic medication that was initially approved in 1991 for the treatment of migraine and cluster headaches. Chemically, it is classified as a “triptan” or tryptamine-based agent and is identified as a structural analogue of various alkaloids such as bufotenine and DMT (dimethyltryptamine). When administered following the onset of a …